share_log

Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug

Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug

藥物濫用障礙公司縮小了第二季度淨虧損,報告了大麻素中毒藥物的進展
Benzinga ·  02/15 00:37

The biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) reported its second quarter financial results on Tuesday for the three months ended Dec. 31, 2023,

生物製藥公司Anebulo Pharmaceuticals, Inc.(納斯達克股票代碼:ANEB)週二公佈了截至2023年12月31日的三個月的第二季度財務業績,

The company's primary focus is on developing therapy for acute cannabinoid intoxication (ACI).

該公司的主要重點是開發急性大麻素中毒(ACI)的療法。

"Anebulo continues to make progress towards our goal of becoming the first company to have an approved treatment for acute cannabinoid intoxication," said CEO Richie Cunningham. "Our current efforts are focused on the completion of critical steps needed to support the future Phase 3 studies of selonabant, including efficient scale-up of manufacturing, completion of remaining nonclinical activities, and finalizing the designs of our proposed registrational studies for further discussion with the FDA."

首席執行官裏奇·坎寧安說:“Anebulo在實現我們的目標方面繼續取得進展,即成爲第一家獲得批准的急性大麻素中毒療法的公司。”“我們目前的工作重點是完成支持selonabant未來3期研究所需的關鍵步驟,包括高效擴大生產規模,完成剩餘的非臨床活動,以及完成我們擬議的註冊研究的設計以供與FDA進一步討論。”

See also: Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Says

另見:分析師表示,以藥物濫用障礙爲重點的Anebulo可能成爲有吸引力的收購目標

Q2 2024 Financial Highlights

2024 年第二季度財務摘要

  • Total operating expenses in the second quarter of fiscal 2024 were $2.8 million compared with $3.8 million in the same period in fiscal 2023.
  • Net loss was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 million, or $(0.15) per share, in the second quarter of fiscal 2023.
  • Cash was $6.6 million as of December 31, 2023.
  • As of Dec. 31, 2023, the company had $7.5 million in total assets, down from $11.7 million as of June 30, 2023.
  • 2024財年第二季度的總運營支出爲280萬美元,而2023財年同期爲380萬美元。
  • 淨虧損爲270萬美元,合每股虧損0.11美元,而2023財年第二季度的淨虧損爲380萬美元,合每股虧損0.15美元。
  • 截至2023年12月31日,現金爲660萬美元。
  • 截至2023年12月31日,該公司的總資產爲750萬美元,低於截至2023年6月30日的1170萬美元。

In August, the company received positive feedback from the Food and Drug Administration (FDA) following a type B meeting in July.

在7月的B型會議之後,該公司於8月收到了美國食品藥品監督管理局(FDA)的積極反饋。

The FDA indicated that a single well-controlled study of ANEB-001 in acute cannabinoid intoxication (ACI) patients presenting to the emergency department combined with a larger THC challenge study in volunteers could potentially provide substantial evidence to support a new drug application.

美國食品藥品管理局表示,一項針對急診室就診的急性大麻素中毒(ACI)患者的 ANEB-001 的單一對照研究,以及一項針對志願者的更大規模的四氫大麻酚挑戰研究,有可能爲支持新藥的申請提供大量證據。

Anebulo has also completed dosing in an open-label part C extension of its phase 2 clinical trial to evaluate the safety and efficacy of ANEB-001 at higher challenge doses of THC.

Anebulo 還完成了其 2 期臨床試驗的開放標籤 C 部分的給藥,該試驗旨在評估 ANEB-001 在更高挑戰劑量的四氫大麻酚下的安全性和有效性。

Now read: Antidote For THC? Anebulo Releases Positive Clinical Data Showing Potential Of Its Drug For Treatment Of Acute Cannabinoid Intoxication

現在閱讀:四氫大麻酚的解毒劑?Anebulo發佈了積極的臨床數據,顯示其藥物有可能治療急性大麻素中毒

ANEB Price Action

ANEB 價格走勢

Anebulo's shares traded 4.8780% higher at $2.58 per share at the market close on Tuesday afternoon.

週二下午收盤時,Anebulo的股價上漲了4.8780%,至每股2.58美元。

Benzinga Cannabis Conferences are coming to Los Angeles. Join the Benzinga Cannabis Market Spotlight: California, and unlock the future of cannabis at the premier networking event in Culver City on February 22. Connect with top industry leaders, gain insider insights into the investment landscape and shape the evolving markets in California and beyond. Don't miss this chance to be at the forefront of the cannabis industry's growth and innovation! Join now.

Benzinga大麻會議即將在洛杉磯舉行。加入 “Benzinga大麻市場聚焦:加州”,在2月22日在卡爾弗城舉行的頂級社交活動上解鎖大麻的未來。與頂級行業領導者建立聯繫,獲得對投資格局的內幕見解,塑造加利福尼亞及其他地區不斷變化的市場。千萬不要錯過這個站在大麻行業增長和創新最前沿的機會!立即加入。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論